MA35865B1 - Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant - Google Patents

Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Info

Publication number
MA35865B1
MA35865B1 MA37207A MA37207A MA35865B1 MA 35865 B1 MA35865 B1 MA 35865B1 MA 37207 A MA37207 A MA 37207A MA 37207 A MA37207 A MA 37207A MA 35865 B1 MA35865 B1 MA 35865B1
Authority
MA
Morocco
Prior art keywords
vhc
pharmaceutical formulations
inhibitor
potent
control
Prior art date
Application number
MA37207A
Other languages
English (en)
Inventor
Mathias Braun
Carl Alan Busacca
Feng-Jing Chen
Edwin Louis Gump
Jenness B Majeska
Scott Pennino
Fenghe Qiu
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35865(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA35865B1 publication Critical patent/MA35865B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne divers procédés de stabilisation de formulations pharmaceutiques d'un inhibiteur spécifique du virus de l'hépatite c (vhc) dirigé contre la formation d'un produit de dégradation génotoxique particulier. De tels procédés incluent la régulation de la température, la régulation de l'humidité, la régulation de l'excipient, la régulation de la coquille de la capsule, la basification et une approche de reconstitution.
MA37207A 2012-01-12 2014-07-11 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant MA35865B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12
PCT/US2013/020934 WO2013106506A1 (fr) 2012-01-12 2013-01-10 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Publications (1)

Publication Number Publication Date
MA35865B1 true MA35865B1 (fr) 2014-12-01

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37207A MA35865B1 (fr) 2012-01-12 2014-07-11 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Country Status (27)

Country Link
US (2) US20140037719A1 (fr)
EP (1) EP2802313A1 (fr)
JP (1) JP2015503616A (fr)
KR (1) KR20140109433A (fr)
CN (1) CN104244926A (fr)
AP (1) AP2014007760A0 (fr)
AR (1) AR089710A1 (fr)
AU (1) AU2013208024A1 (fr)
BR (1) BR112014017058A8 (fr)
CA (1) CA2861041A1 (fr)
CL (1) CL2014001783A1 (fr)
CO (1) CO7000774A2 (fr)
EA (1) EA201400808A1 (fr)
EC (1) ECSP14013104A (fr)
HK (1) HK1204982A1 (fr)
IL (1) IL233550A0 (fr)
IN (1) IN2014DN05759A (fr)
MA (1) MA35865B1 (fr)
MX (1) MX2014008205A (fr)
NZ (1) NZ626353A (fr)
PE (1) PE20141817A1 (fr)
PH (1) PH12014501598A1 (fr)
SG (1) SG11201404042VA (fr)
TN (1) TN2014000295A1 (fr)
TW (1) TW201340969A (fr)
UY (1) UY34569A (fr)
WO (1) WO2013106506A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
SG11201507223TA (en) 2013-03-15 2015-10-29 Gilead Sciences Inc Macrocyclic and bicyclic inhibitors of hepatitis c virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
RS51294B (sr) 2003-05-21 2010-12-31 Boehringer Ingelheim International Gmbh. Inhibitorna jedinjenja za hepatitis c
JP5156374B2 (ja) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
WO2006130552A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement du virus de l'hepatite c
SI2331538T1 (sl) 2008-09-16 2014-06-30 Boehringer Ingelheim International Gmbh Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV
RS53121B (en) * 2008-11-21 2014-06-30 Boehringer Ingelheim International Gmbh PHARMACEUTICAL COMPOSITION OF POWERFUL HCV INHIBITOR FOR ORAL USE
EP2451438B8 (fr) 2009-07-07 2014-04-09 Boehringer Ingelheim International GmbH Composition pharmaceutique pour un inhibiteur de protéase virale de l'hépatite c

Also Published As

Publication number Publication date
ECSP14013104A (es) 2015-11-30
IL233550A0 (en) 2014-08-31
IN2014DN05759A (fr) 2015-04-10
UY34569A (es) 2013-07-31
AP2014007760A0 (en) 2014-07-31
AU2013208024A1 (en) 2014-07-10
CN104244926A (zh) 2014-12-24
NZ626353A (en) 2016-02-26
MX2014008205A (es) 2014-08-08
PE20141817A1 (es) 2014-12-17
US20150190458A1 (en) 2015-07-09
KR20140109433A (ko) 2014-09-15
TW201340969A (zh) 2013-10-16
EP2802313A1 (fr) 2014-11-19
WO2013106506A1 (fr) 2013-07-18
US20140037719A1 (en) 2014-02-06
BR112014017058A2 (pt) 2017-06-13
CL2014001783A1 (es) 2014-12-12
AR089710A1 (es) 2014-09-10
CA2861041A1 (fr) 2013-07-18
PH12014501598A1 (en) 2014-10-08
CO7000774A2 (es) 2014-07-21
BR112014017058A8 (pt) 2017-07-04
TN2014000295A1 (en) 2015-12-21
EA201400808A1 (ru) 2015-02-27
HK1204982A1 (en) 2015-12-11
SG11201404042VA (en) 2014-08-28
JP2015503616A (ja) 2015-02-02

Similar Documents

Publication Publication Date Title
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
MX2023006541A (es) Formulaciones de dosis fija.
EA201071035A1 (ru) Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения
WO2012158945A3 (fr) Compositions et procédés pour traiter les maladies de charcot-marie-tooth et les maladies neuronales associées
ZA201301391B (en) Pharmaceutical formulations containing rifaximin,processes for their obtainment and method of treating intestinal disease
ATE536172T1 (de) Ezetimibzusammensetzungen
WO2013003827A3 (fr) Formulations de macrogol 15 hydroxystéarate
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
IN2013CH05441A (fr)
WO2013175494A3 (fr) Formulations pharmaceutiques à libération contrôlée d'inhibiteurs directs de la thrombine
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
WO2014016754A3 (fr) Compositions pharmaceutiques d'inhibiteur de la pompe à protons
MX2013007661A (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.
MA35865B1 (fr) Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant
MY169266A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
PT2247573E (pt) Sais carbónicos e de ácido sulfúrico de ésteres de 3-(2,2,2- trimetil-hidrazínio)propionato e sua utilização para a preparação de di-hidrato de 3-(2,2,2-trimetilhidrazínio) propionato
WO2016069542A3 (fr) Composés de lactone, leurs procédés de préparation et d'utilisation
EP2933254A4 (fr) Nouveau composé, sel pharmaceutiquement acceptable ou isomère optique de celui-ci, procédé de préparation de celui-ci et composition pharmaceutique pour la prévention ou le traitement de maladies virales contenant celui-ci en tant que principe actif
CA2865484A1 (fr) Composition pharmaceutique a liberation controlee stabilisee comprenant du gliclazide
MX2013011884A (es) Composiciones farmaceuticas de liberacion modificada de desvenlafaxina.
WO2011115599A3 (fr) Formulations de comprimé délitant par voie orale de donépézil et procédé pour préparer celui-ci
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.
WO2013168179A3 (fr) Formulations pharmaceutiques à libération contrôlée d'agents antiviraux
UA110882C2 (uk) Фармацевтична композиція та спосіб її отримання